Full Disclosure Trading Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Full Disclosure Trading

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: seminole who wrote (6391)	7/25/2003 12:13:19 PM
From: seminole	Read Replies (1) of 13403

OT;11:58AM MGI Pharma spikes ahead of FDA review (MOGN) 28.81 +2.20: Stock has spiked more than a point in the past 20 min; it's worth noting that MOGN has an FDA review (PDUFA) date for Palonosetron (Aloxi) of July 27. Palonosetron is an anti-nausea drug licenced from Helsinn Healthcare SA with a peak sales potential of $800 mln, making it the lead drug candidate for the co. CE Unterberg in previewing the event is expecting an approval. The co has added 30 people to its sales force (raising in to 80 total) ahead of the FDA review date, which can be considered an indication of confidence in approval.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next